Goran L, Negreanu AM, Stemate A, Negreanu L. Capsule endoscopy: Current status and role in Crohn’s disease. World J Gastrointest Endosc 2018; 10(9): 184-192 [PMID: PMC6162247 DOI: 10.4253/wjge.v10.i9.184]
Corresponding Author of This Article
Lucian Negreanu, MD, PhD, Professor, Internal Medicine 2-Gastroenterology Department, University Hospital, Carol Davila University, 169, Splaiul Independentei Street, Sector 5, Bucharest 050098, Romania. lucian.negreanu@umfcd.ro
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Endosc. Sep 16, 2018; 10(9): 184-192 Published online Sep 16, 2018. doi: 10.4253/wjge.v10.i9.184
Capsule endoscopy: Current status and role in Crohn’s disease
Loredana Goran, Ana Maria Negreanu, Ana Stemate, Lucian Negreanu
Loredana Goran, Ana Maria Negreanu, Ana Stemate, Lucian Negreanu, Internal Medicine 2-Gastroenterology Department, University Hospital, Carol Davila University, Bucharest 050098, Romania
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Lucian Negreanu, MD, PhD, Professor, Internal Medicine 2-Gastroenterology Department, University Hospital, Carol Davila University, 169, Splaiul Independentei Street, Sector 5, Bucharest 050098, Romania. lucian.negreanu@umfcd.ro
Telephone: +40-72-9439249
Received: April 8, 2018 Peer-review started: April 8, 2018 First decision: April 26, 2018 Revised: July 1, 2018 Accepted: August 4, 2018 Article in press: August 5, 2018 Published online: September 16, 2018 Processing time: 162 Days and 15.2 Hours
Core Tip
Core tip: The target in inflammatory bowel disease has changed during the last years from controlling symptoms to achieving mucosal healing as the final goal of treatment. C-reactive protein and fecal calprotectin have proved their efficacy in monitoring and guiding the treatment in Crohn’s disease as shown by the pivotal CALM study. More and more evidence tends to support a role of iterative capsule endoscopy (CE) examinations. Evidence is based on small bowel and pillcam colon 2 capsule examinations. The appearance of the new capsule from Medtronic-Pillcam Crohn’s might be an important step forward in diagnosis, evaluating disease extent, the severity of the disease, prognosis, management in a treat to target approach, with treatment modifications according to the data from CE examination.
